Nature Reviews Gastroenterology & Hepatology

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Retrieved on: 
星期二, 九月 26, 2023
Nature Reviews Gastroenterology & Hepatology, Inflammation, Cirrhosis, Macrophage, Therapy, Boudes, GALT, Cell, Discovery, Hepatology, Patient, Fibrosis, Non-Euclidean geometry, Liver, Pharmaceutical industry

The Company will present an update on its belapectin liver cirrhosis program during the Fibrosis and Inflammation session.

Key Points: 
  • The Company will present an update on its belapectin liver cirrhosis program during the Fibrosis and Inflammation session.
  • The presentation, titled “Targeting Activated Macrophages to Improve Liver Cirrhosis: The Discovery and Clinical Translation of Belapectin,” will take place Wednesday, September 27, at 2:25 PM EDT and will be delivered by Dr. Pol F. Boudes, M.D., Chief Medical Officer of Galectin Therapeutics.
  • Boudes commented: “The role of activated macrophages in the establishment and progression of liver cirrhosis is predominant1.
  • These cells, when activated, invade the liver, and produce galectin-3, a pro-inflammatory and pro-fibrotic molecule.

New study shows that WATS3D increases diagnostic yield of dysplasia in Barrett's esophagus, regardless of segment length

Retrieved on: 
星期三, 八月 2, 2023
Male, ASGE, University, Diagnosis, Barrett's esophagus, American Society for Gastrointestinal Endoscopy, Pathology, Intestinal metaplasia, Gastrointestinal Endoscopy, MBA, University of Rochester Medical Center, Consultant, Nature Reviews Gastroenterology & Hepatology, Gastrointestinal tract, Dysplasia, Hepatology, Patient, Division, Gastroenterology, GIE, Epithelium, Northwell Health, Society, Medical device, Endoscopy, MD, Fellowship of the Royal Colleges of Surgeons

Regardless of segment length, WATS3D is highly effective at increasing the diagnostic yield of intestinal metaplasia and dysplasia.

Key Points: 
  • Regardless of segment length, WATS3D is highly effective at increasing the diagnostic yield of intestinal metaplasia and dysplasia.
  • "WATS3D has previously shown diagnostic effectiveness for patients with known or suspected BE," said the lead author of the study, Dr. Arvind Trindade, Regional Director of Endoscopy, Northwell Health.
  • "This new study focuses on WATS3D performance in short versus long segment esophageal columnar-lined mucosa."
  • The adjunctive and absolute yields of WATS3D were calculated according to the length of the patient's BE segment.

American College of Gastroenterology and American Gastroenterological Association Invest in Oshi Health to Accelerate Adoption of Hybrid Digestive Health Care

Retrieved on: 
星期二, 六月 13, 2023
Insurance, University of California, San Diego Performance-Based Skills Assessment, FACG, Partnership, University, Health policy, Diabetes, American Gastroenterological Association, Workplace, Quality of life, Human, MBA, Science, Nature Reviews Gastroenterology & Hepatology, AGAF, AGA, Patient, AHIP, Outline of health sciences, DHPA, System, American College of Gastroenterology, American College, Treasurer, Society, GI, ACG, Nursing, Pharmaceutical industry, Oshi, MD, Gastroenterology

PORTLAND, Ore., June 13, 2023 (GLOBE NEWSWIRE) -- AHIP 2023 CONFERENCE -- Oshi Health today announced strategic investments by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) GI Opportunity Fund .

Key Points: 
  • PORTLAND, Ore., June 13, 2023 (GLOBE NEWSWIRE) -- AHIP 2023 CONFERENCE -- Oshi Health today announced strategic investments by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) GI Opportunity Fund .
  • As part of the arrangement, both the ACG and AGA have made strategic financial investments in Oshi Health as an illustration of the importance of providing patients access to the evidence-based, multidisciplinary care offered by Oshi.
  • “As an organization, ACG aims to empower gastroenterologists to embrace the science supporting new guidelines and how to integrate them into clinical practice.
  • Lack of access to multidisciplinary care and support between traditional GI care visits can result in poor patient outcomes and avoidable emergency services.

BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

Retrieved on: 
星期一, 三月 13, 2023
Paracentesis, Terlipressin, Liver, Publication, Nature Reviews Gastroenterology & Hepatology, Ascites, Cirrhosis, Abdomen, Temperature, Patient, Incidence, SOC, Standard of care, FDA, Grade 2, Cancer, Pharmaceutical industry, Hepatology, Medicine, Gastroenterology

This improvement was significantly different from those treated with SOC only who experienced a mean increase in ascites fluid of 3.1% (BIV201 vs. SOC p=0.05).

Key Points: 
  • This improvement was significantly different from those treated with SOC only who experienced a mean increase in ascites fluid of 3.1% (BIV201 vs. SOC p=0.05).
  • Patients who completed the treatment with BIV201 experienced a 53% reduction in ascites fluid (p=0.001), which was significantly different from those treated with SOC (p=0.007).
  • The current trial (NCT04112199) evaluates the efficacy of BIV201 combined with standard-of-care (SOC), compared to SOC alone, for the treatment of refractory ascites.
  • “Compelling data from the first 15 patients led us to pause enrollment,” commented Cuong Do, BioVie’s President and CEO.

Autoimmune Liver Disease Forum to Examine Solutions for Improving Health Outcomes

Retrieved on: 
星期二, 三月 14, 2023
Hepatology, PBC, Autoimmune hepatitis, Intercept, Caregiver, Organization, Ipsen, Primary biliary cholangitis, AIH, ALF, Primary sclerosing cholangitis, Quality of life, Inspiration, MD, Patient, Overalls, American Liver Foundation, Stanford University School of Medicine, Nature Reviews Gastroenterology & Hepatology, Immune system, Division, Icahn School of Medicine at Mount Sinai, Diagnosis, PSC, Mount Sinai, Physician, Liver, Human, Pharmaceutical industry, Medical imaging, Vaccine, Dietary supplement, Medicine

FAIRFIELD, N.J., March 14, 2023 /PRNewswire/ -- A two-day virtual event on March 15th and 16th will bring together more than 350 patients, caregivers, hepatologists, primary care providers, patient advocacy organizations and industry representatives all with one goal in mind—find solutions to improve health outcomes for all those suffering from rare autoimmune liver diseases. The group will address two main questions: how can people avoid misdiagnosis and achieve earlier diagnosis; and how can we reduce the patient burden to improve the overall patient experience.

Key Points: 
  • Two-day Autoimmune Liver Disease Forum brings together key stakeholders to improve health outcomes for patients.
  • "We were overwhelmed with the positive response from our community for our Autoimmune Liver Disease Forum .
  • An autoimmune liver disease develops when your own immune system mistakes normal, healthy tissue for a foreign body.
  • The Autoimmune Liver Disease Forum is made possible through generous support provided by lead sponsor Ipsen and partnering sponsor Intercept.

CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care

Retrieved on: 
星期二, 八月 2, 2022
General Health, Health, Surgery, Telemedicine, Virtual Medicine, Hepatology, Hospital readmission, SEC, Incidence, Heart transplantation, Nature Reviews Gastroenterology & Hepatology, West Valley Hospital (Oregon), Late, Hospital, Lung, Transplant, Caregiver, MD, Kidney transplantation, Patient, Ann Harrison (lung transplant recipient), Heart, Nasdaq, Precision medicine, Medical City, Annual report, Kidney, Survival, Internet, Surgery, Pharmaceutical industry, Medical imaging, Dentistry, Early

CareDx is committed to driving forward innovative digital health solutions to support patients at all stages of their transplant journey and we are especially proud to deliver this new, convenient patient monitoring offering to augment their care, said Reg Seeto, CareDx CEO and President.

Key Points: 
  • CareDx is committed to driving forward innovative digital health solutions to support patients at all stages of their transplant journey and we are especially proud to deliver this new, convenient patient monitoring offering to augment their care, said Reg Seeto, CareDx CEO and President.
  • AlloHome offers personalized, real-time monitoring to ensure that all patients, including those in underserved communities who may have difficulty accessing healthcare, receive the high-quality continuous oversight and care that their condition requires.
  • Regular monitoring of critical patient health data through AlloHome improves continuity of care, enables the opportunity for earlier interventions, helps prevent readmission, and improves patient engagement at every step along the transplant journey.
  • This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDxs AlloHome solution.

Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board

Retrieved on: 
星期二, 四月 26, 2022
University Hospitals Cleveland Medical Center, Hepatic encephalopathy, UMKC, University, Luke the Evangelist, CAP, Liver transplantation, U.S. Securities and Exchange Commission, Security (finance), Coronavirus Scientific Advisory Board (Turkey), Editorial board, Annual report, ASAIO Journal, Community-acquired pneumonia, CA, Nature Reviews Gastroenterology & Hepatology, Associate, GLOBE, Death, Risk, Securities Act of 1933, Patient, Sepsis, Inflammation, SAN, OTC Markets Group, Hospital, Infection, Gastroenterology, Securities Exchange Act of 1934, Company, Principal, Iowa State University, European Journal of Gastroenterology & Hepatology, Liver, Book, Section, National Association Medical Staff Services, Therapy, Septic shock, Internal medicine, Pharmaceutical industry, Medicine, Hepatology, Microbiology

to its Scientific Advisory Board.

Key Points: 
  • to its Scientific Advisory Board.
  • Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated conditions that precipitate sepsis, the leading cause of hospital deaths worldwide.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.
  • All forward-looking statements contained in this report speak only as of the date on which they were made.

Versantis Appoints Leading Hepatologist Prof Dr Katharina Staufer as Chief Medical Officer

Retrieved on: 
星期二, 十月 19, 2021
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ODD, Cirrhosis, Center, Nature Reviews Gastroenterology & Hepatology, Liposome, Association, Internal medicine, Kidney, Institute of Liver and Biliary Sciences, EASL, Mark (given name), Medical school, EMA, ETH Zurich, American Association for the Study of Liver Diseases, Adult, Inselspital, Board, Professor, Center for Molecular Neurobiology Hamburg, AASLD, Molecular biology, Associate, FDA, CEO, Brain, Patient, University, Industry, University Medical Center, Gastroenterology, COO, University Medical Center Hamburg-Eppendorf, European Association for the Study of the Liver, U.S. FDA, ACLF, American Association, Medical University of Vienna, Therapy, University of Hamburg, Trial of the century, Medical imaging, Pharmaceutical industry

Versantis AG, a clinical-stage company developing novel therapies for rare liver diseases and rare pediatric diseases, today announced the appointment of Prof Dr Katharina Staufer as Chief Medical Officer.

Key Points: 
  • Versantis AG, a clinical-stage company developing novel therapies for rare liver diseases and rare pediatric diseases, today announced the appointment of Prof Dr Katharina Staufer as Chief Medical Officer.
  • Prof Staufer is a gastroenterologist and hepatologist with a strong clinical and scientific background in metabolic liver disease, liver cirrhosis and transplant hepatology, including orphan liver diseases.
  • We look forward to the contribution that Katharina will bring to unfold the full potential of VS-01 in our key adult and pediatric indications.
  • Versantis is a clinical stage company focused on addressing the growing, un-met medical need in liver diseases.